Nasopharyngeal carcinoma (NPC) is a common malignant tumor in Southern China and
South-East Asia. Regardless of initiative high response to radiotherapy, parts of patients still …

Introduction: Systemic therapy is crucial to the management of locally advanced or
metastatic nasopharyngeal cancer (NPC). Despite initial responses, the benefits of …

Background Various studies have assessed the prognostic value of epidermal growth factor
receptor (EGFR) overexpression in nasopharyngeal carcinoma (NPC), but their results …

Background This single‐center, phase II study assessed the safety/tolerability and initial
efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with …

Nasopharyngeal carcinoma (NPC) is endemic in Southern China, and the South-East Asia
including Hong Kong. We still see patients recur after primary treatment with radiotherapy or …

Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal
carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR …

Background Little is known about the prognostic difference of anti-EGFR therapy, cetuximab
(CTX) or nimotuzumab (NTZ), concurrently with induction chemotherapy (IC, investigational …

Epstein–Barr virus (EBV), a type 4 γ herpes virus, is recognized as a causative agent in
nasopharyngeal carcinoma (NPC). Incidence of EBV-positive NPC have grown in recent …

Background: Epidermal growth factor receptor (EGFR) has been reported to play a
prognostic role in nasopharyngeal carcinoma (NPC). Nevertheless, the effect of EGFR …

Objective This study aimed to evaluate the efficacy and safety in locoregionally advanced
nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) …